Single compartment drug delivery
Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a case. It is, however, common for enzymes or receptors that are integral to disease to be structurally similar or ide...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Elsevier
2016
|
| Online Access: | http://hdl.handle.net/1721.1/101146 https://orcid.org/0000-0003-2379-6139 https://orcid.org/0000-0001-6694-6761 https://orcid.org/0000-0002-7963-8706 https://orcid.org/0000-0001-8586-6900 https://orcid.org/0000-0002-7836-415X https://orcid.org/0000-0003-4255-0492 |
| _version_ | 1826214287920594944 |
|---|---|
| author | Cima, Michael J. Daniel, Karen Mantzavinou, Aikaterini Ong, Qunya Sy, Jay C. Santini, John Blankschtein, Daniel Tanenbaum, Laura Melanie Lee, Heejin, 1976- Spencer, Kevin C Schoellhammer, Carl Magnus Langer, Robert S |
| author2 | Harvard University--MIT Division of Health Sciences and Technology |
| author_facet | Harvard University--MIT Division of Health Sciences and Technology Cima, Michael J. Daniel, Karen Mantzavinou, Aikaterini Ong, Qunya Sy, Jay C. Santini, John Blankschtein, Daniel Tanenbaum, Laura Melanie Lee, Heejin, 1976- Spencer, Kevin C Schoellhammer, Carl Magnus Langer, Robert S |
| author_sort | Cima, Michael J. |
| collection | MIT |
| description | Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a case. It is, however, common for enzymes or receptors that are integral to disease to be structurally similar or identical to those that play important biological roles in normal tissues of the body. Additionally, systemic administration may not lead to local drug concentrations high enough to yield disease modification because of rapid systemic metabolism or lack of sufficient partitioning into the diseased tissue compartment. This review focuses on drug delivery methods that physically target drugs to individual compartments of the body. Compartments such as the bladder, peritoneum, brain, eye and skin are often sites of disease and can sometimes be viewed as “privileged,” since they intrinsically hinder partitioning of systemically administered agents. These compartments have become the focus of a wide array of procedures and devices for direct administration of drugs. We discuss the rationale behind single compartment drug delivery for each of these compartments, and give an overview of examples at different development stages, from the lab bench to phase III clinical trials to clinical practice. We approach single compartment drug delivery from both a translational and a technological perspective. |
| first_indexed | 2024-09-23T12:56:31Z |
| format | Article |
| id | mit-1721.1/101146 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T12:56:31Z |
| publishDate | 2016 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | mit-1721.1/1011462022-09-28T11:03:42Z Single compartment drug delivery Cima, Michael J. Daniel, Karen Mantzavinou, Aikaterini Ong, Qunya Sy, Jay C. Santini, John Blankschtein, Daniel Tanenbaum, Laura Melanie Lee, Heejin, 1976- Spencer, Kevin C Schoellhammer, Carl Magnus Langer, Robert S Harvard University--MIT Division of Health Sciences and Technology Massachusetts Institute of Technology. Department of Chemical Engineering Massachusetts Institute of Technology. Department of Materials Science and Engineering Koch Institute for Integrative Cancer Research at MIT Cima, Michael J. Tanenbaum, Laura Melanie Mantzavinou, Aikaterini Spencer, Kevin C. Ong, Qunya Sy, Jay C. Schoellhammer, Carl Blankschtein, Daniel Langer, Robert Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a case. It is, however, common for enzymes or receptors that are integral to disease to be structurally similar or identical to those that play important biological roles in normal tissues of the body. Additionally, systemic administration may not lead to local drug concentrations high enough to yield disease modification because of rapid systemic metabolism or lack of sufficient partitioning into the diseased tissue compartment. This review focuses on drug delivery methods that physically target drugs to individual compartments of the body. Compartments such as the bladder, peritoneum, brain, eye and skin are often sites of disease and can sometimes be viewed as “privileged,” since they intrinsically hinder partitioning of systemically administered agents. These compartments have become the focus of a wide array of procedures and devices for direct administration of drugs. We discuss the rationale behind single compartment drug delivery for each of these compartments, and give an overview of examples at different development stages, from the lab bench to phase III clinical trials to clinical practice. We approach single compartment drug delivery from both a translational and a technological perspective. National Institutes of Health (U.S.) (Grant R37EB000244) National Institutes of Health (U.S.) (Grant K99EB016690) National Institutes of Health (U.S.) (Grant R01EB016101) Massachusetts Institute of Technology. Institute for Soldier Nanotechnologies (Grant W911NF-13-D-0001) Singapore. Agency for Science, Technology and Research National Science Foundation (U.S.). Graduate Research Fellowship David H. Koch Institute for Integrative Cancer Research at MIT (Bridge Project) David H. Koch Institute for Integrative Cancer Research at MIT (Core Grant) 2016-02-09T20:13:13Z 2016-02-09T20:13:13Z 2014-05 2014-02 Article http://purl.org/eprint/type/JournalArticle 01683659 http://hdl.handle.net/1721.1/101146 Cima, Michael J., Heejin Lee, Karen Daniel, Laura M. Tanenbaum, Aikaterini Mantzavinou, Kevin C. Spencer, Qunya Ong, et al. “Single Compartment Drug Delivery.” Journal of Controlled Release 190 (September 2014): 157–71. https://orcid.org/0000-0003-2379-6139 https://orcid.org/0000-0001-6694-6761 https://orcid.org/0000-0002-7963-8706 https://orcid.org/0000-0001-8586-6900 https://orcid.org/0000-0002-7836-415X https://orcid.org/0000-0003-4255-0492 en_US http://dx.doi.org/10.1016/j.jconrel.2014.04.049 Journal of Controlled Release Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier PMC |
| spellingShingle | Cima, Michael J. Daniel, Karen Mantzavinou, Aikaterini Ong, Qunya Sy, Jay C. Santini, John Blankschtein, Daniel Tanenbaum, Laura Melanie Lee, Heejin, 1976- Spencer, Kevin C Schoellhammer, Carl Magnus Langer, Robert S Single compartment drug delivery |
| title | Single compartment drug delivery |
| title_full | Single compartment drug delivery |
| title_fullStr | Single compartment drug delivery |
| title_full_unstemmed | Single compartment drug delivery |
| title_short | Single compartment drug delivery |
| title_sort | single compartment drug delivery |
| url | http://hdl.handle.net/1721.1/101146 https://orcid.org/0000-0003-2379-6139 https://orcid.org/0000-0001-6694-6761 https://orcid.org/0000-0002-7963-8706 https://orcid.org/0000-0001-8586-6900 https://orcid.org/0000-0002-7836-415X https://orcid.org/0000-0003-4255-0492 |
| work_keys_str_mv | AT cimamichaelj singlecompartmentdrugdelivery AT danielkaren singlecompartmentdrugdelivery AT mantzavinouaikaterini singlecompartmentdrugdelivery AT ongqunya singlecompartmentdrugdelivery AT syjayc singlecompartmentdrugdelivery AT santinijohn singlecompartmentdrugdelivery AT blankschteindaniel singlecompartmentdrugdelivery AT tanenbaumlauramelanie singlecompartmentdrugdelivery AT leeheejin1976 singlecompartmentdrugdelivery AT spencerkevinc singlecompartmentdrugdelivery AT schoellhammercarlmagnus singlecompartmentdrugdelivery AT langerroberts singlecompartmentdrugdelivery |